Loading...
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
BACKGROUND: Treatment with MD1003 (high-dose biotin) showed promising results in progressive multiple sclerosis (MS) in a pilot open-label study. OBJECTIVE: To confirm the efficacy and safety of MD1003 in progressive MS in a double-blind, placebo-controlled study. METHODS: Patients (n = 154) with a...
Na minha lista:
| Udgivet i: | Mult Scler |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5098693/ https://ncbi.nlm.nih.gov/pubmed/27589059 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458516667568 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|